REG-Genmab Announces Financial Results for the First Half of 2026
Genmab reported positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, demonstrating a statistically significant improvement in progression-free survival. First-half revenue rose 25% year-over-year to $2.05 billion, driven by higher royalties from DARZALEX and Kesimpta, as well as 48% growth in EPKINLY net sales.
Key figures
- Revenue
- 2051000000
- Guidance
- 2026 Revenue $4.325B-$4.525B, raised from $4.065B-$4.395B
- Revenue Yoy
- 25%
- Phase of trial
- Phase 3
- H1 epkinly sales
- 312000000
- H1 royalty revenue
- 1708000000
- H1 darzalex net sales
- 8171000000
- H1 adjusted operating profit
- 656000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.